NVCR - ノボキュア (NovoCure Limited) ノボキュア

 NVCRのチャート


 NVCRの企業情報

symbol NVCR
会社名 NovoCure Ltd (ノボキュア)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ノボキュア(NovoCure Limited)は商業段階の腫瘍学会社である。同社は固形癌細胞分裂を破壊するために特定の周波数に調整された電場を使用するTTFieldsと呼ばれる療法を中心とする癌治療法の開発に従事する。TTFieldsはグリア芽腫(GBM)の治療に使用され、臨床パイプラインを通じて複数の固形腫瘍適応症におけるTTFieldのプログラム検査を進めるために使用される。GBMの臨床的・商業的発展に加えて、TTFieldは脳転移、非小細胞肺癌(NSCLC)、膵臓癌、卵巣癌および中皮腫におけるTTFieldの使用を評価する臨床試験を計画または実施している。TTFieldは、ポータブルな医療機器を通じて提供される。完全な送達システムは、継続的な癌治療を受けながら患者が日々の活動に慣れることができるように設計され、携帯用電界ジェネレータ、トランスデューサアレイ、充電式バッテリ、アクセサリーを含む。   ノボキュアは英国の医療機器メ―カ―。主に固形がん腫瘍の治療向け医療機器の開発に従事する。同社開発の「TTFields」は非侵襲性の腫瘍治療電場システムで、細胞分裂阻止の治療電場を発生させ通常のプロセスを阻害し、がん細胞を死滅する。一般的ながん治療である手術、放射線治療、抗がん剤治療に合わせ、更なる治療法を開発する。本社は英国ジャ―ジ―島。   Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
本社所在地 No. 4 The Forum Grenville Street St. Helier Jersey JE2 4UF GBR
代表者氏名 William F. Doyle ウィリアムF.ドイル
代表者役職名 Executive Chairman of the Board 取締役会長
電話番号 +44 1534-75-6700
設立年月日 36557
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 495人
url www.novocure.com
nasdaq_url https://www.nasdaq.com/symbol/nvcr
adr_tso
EBITDA EBITDA(百万ドル) -21.49100
終値(lastsale) 48.2
時価総額(marketcap) 4477903392
時価総額 時価総額(百万ドル) 3966.939
売上高 売上高(百万ドル) 217.40900
企業価値(EV) 企業価値(EV)(百万ドル) 3897.179
当期純利益 当期純利益(百万ドル) -93.47700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Novocure Ltd revenues increased 55% to $113.6M. Net loss decreased 8% to $36.2M. Revenues reflect Europe_Middle East_Africa (EMEA) (Region) segment increase from $12.6M to $32.4M United States segment increase of 32% to $79.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.45 to -$0.40.

 NVCRのテクニカル分析


 NVCRのニュース

   Novocure to Report Third Quarter 2021 Financial Results  2021/10/04 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced that it will report financial results for the third quarter 2021 on Thursday, October 28, 2021.
   Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China  2021/10/04 11:30:00 Intrado Digital Media
Final data collection is expected in the first half of 2022
   Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China  2021/10/04 11:30:00 Business Wire
ST. HELIER, Jersey & SHANGHAI--(BUSINESS WIRE)-- #GastricCancer--Novocure and Zai Lab announced that the last patient has been enrolled in a phase 2 pilot trial of TTFields plus chemotherapy in gastric cancer.
   Novocure To Test Its Tumor Treating Fields With Roche''s Tecentriq In Pancreatic Cancer  2021/09/14 12:34:37 Benzinga
Novocure Ltd (NASDAQ: NVCR ) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC: RHHBY ) to develop Tumor Treating Fields (TTFields) together with Roche''s atezolizumab in metastatic pancreatic ductal adenocarcinoma (mPDAC). The phase 2 study was designed to test the safety and efficacy of TTFields together with atezolizumab, gemcitabine, and nab-paclitaxel as Full story available on Benzinga.com
   Novocure in pact with Roche to test potential of Tumor Treating Fields in pancreatic cancer  2021/09/14 11:53:15 Seeking Alpha
   Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program  2021/07/15 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure today announced the recipients of the 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research program.
   Novocure to Report Second Quarter 2021 Financial Results  2021/07/08 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced today that it will report financial results for the second quarter 2021 on July 29, 2021, before the U.S. financial markets open.
   NovoCure: High-Income Options Trade, Bullish Vertical Put Spread  2021/07/02 17:03:17 Seeking Alpha
   Analyzing NovoCure''s Unusual Options Activity  2021/07/02 16:24:01 Benzinga
Shares of NovoCure (NASDAQ: NVCR ) saw some unusual options activity on Friday. Following the unusual option alert, the stock price moved down to $184.64. Sentiment: BEARISH Option Type: TRADE Trade Type: CALL Expiration Date: 2021-09-17 Strike Price: $230.00 Volume: 253 Open Interest: 60 Three Indications Of Unusual Options Activity Exceptionally large volume (compared to historical averages) is one reason for which options market activity can be considered unusual. The volume of options activity refers to the number of contracts traded over a given time period. The number of contracts that have been traded, but not yet closed by either counterparty, is called open interest. A contract cannot be considered closed until there exists both a buyer and seller for it. Another indicator of unusual options activity is the trading of a contract with an expiration date in Full story available on Benzinga.com
   Arcturus wins bullish call on vaccine potential, Novocure downgraded in today''s analyst action  2021/07/02 13:15:18 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ノボキュア NVCR NovoCure Limited)

 twitter  (公式ツイッターやCEOツイッターなど)